具 体 内 容 详 见 公 司 于 2025 年 12 月 10 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）以及公司指定信息披露媒体披露的《关于使用部分闲置募集 资金进行现金管理的公告》（公告编号：2025-004）。 二、本次使用部分闲置募集资金进行现金管理赎回的情况 证券代码：603334 证券简称：丰倍生物 公告编号：2026-003 苏州丰倍生物科技股份有限公司 关于使用部分闲置募集资金进行现金管理 到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、使用部分闲置募集资金进行现金管理概述 苏州丰倍生物科技股份有限公司（以下简称"公司"）于2025年12月9日召 开第二届董事会第七次会议，审议通过了《关于使用部分闲置募集资金进行现金 管理的议案》，同意公司使用不超过人民币3亿元（含本数）的闲置募集资金（含 超募资金）进行现金管理，投资安全性高、流动性好、低风险、稳健型的保本型 理财产品，现金管理额度有效期自董事会审议通过之日起12个月之内有效。在上 述额度及有效期内，资金 ...

证券代码：603334 证券简称：丰倍生物 公告编号：2026-002 苏州丰倍生物科技股份有限公司 关于使用部分闲置募集资金进行现金管理 到期赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、使用部分闲置募集资金进行现金管理概述 苏州丰倍生物科技股份有限公司（以下简称"公司"）于2025年12月9日召 开第二届董事会第七次会议，审议通过了《关于使用部分闲置募集资金进行现金 管理的议案》，同意公司使用不超过人民币3亿元（含本数）的闲置募集资金（含 超募资金）进行现金管理，投资安全性高、流动性好、低风险、稳健型的保本型 理财产品，现金管理额度有效期自董事会审议通过之日起12个月之内有效。在上 述额度及有效期内，资金可循环滚动使用，期限内任一时点的交易金额（含前述 投资的收益进行再投资的相关金额）不应超过投资额度。保荐机构国泰海通证券 股份有限公司对该事项出具了无异议的核查意见。 具 体 内 容 详 见 公 司 于 2025 年 12 月 10 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.c ...

Group 1 - The core viewpoint of the news highlights the financial performance and stock activity of Fengbei Biotechnology, indicating a decline in stock price and significant financing activity on February 25 [1] - On February 25, Fengbei Biotechnology's stock dropped by 3.55%, with a trading volume of 174 million yuan, and a net financing outflow of 15.48 million yuan [1] - As of February 25, the total balance of margin trading for Fengbei Biotechnology was 79.81 million yuan, accounting for 4.77% of its market capitalization [1] Group 2 - As of December 10, the number of shareholders for Fengbei Biotechnology decreased by 50.19% to 27,600, while the average circulating shares per person increased by 100.77% to 1,123 shares [2] - For the period from January to September 2025, Fengbei Biotechnology reported a revenue of 2.251 billion yuan, representing a year-on-year growth of 62.32%, and a net profit attributable to shareholders of 117 million yuan, up 35.32% year-on-year [2]

Group 1 - The core viewpoint of the news is that Fengbei Bio experienced a decline in stock price and trading volume, with significant net financing outflows on February 12, indicating potential investor concerns [1] - On February 12, Fengbei Bio's stock price fell by 3.03%, with a trading volume of 199 million yuan. The net financing buy was -6.46 million yuan, with a total financing balance of 97.52 million yuan, accounting for 5.87% of the circulating market value [1] - The company specializes in the comprehensive utilization of waste oil resources, with its main business revenue composition being 91.18% from waste resource utilization, including 79.60% from bio-based materials and 11.58% from biofuels [1] Group 2 - As of December 10, the number of shareholders for Fengbei Bio was 27,600, a decrease of 50.19% from the previous period, while the average circulating shares per person increased by 100.77% [2] - For the period from January to September 2025, Fengbei Bio achieved an operating income of 2.251 billion yuan, representing a year-on-year growth of 62.32%, and a net profit attributable to the parent company of 117 million yuan, up 35.32% year-on-year [2]

Group 1 - The biodiesel sector experienced a decline of 0.82% compared to the previous trading day, with Fengbei Bio leading the losses [1] - On the same day, the Shanghai Composite Index closed at 4134.02, up by 0.05%, while the Shenzhen Component Index closed at 14283.0, up by 0.86% [1] - The net capital outflow from the biodiesel sector amounted to 55.50 million yuan, while retail investors saw a net inflow of 9.40 million yuan [1] Group 2 - The main funds in the biodiesel sector had a net outflow of 55.50 million yuan, while speculative funds had a net inflow of 46.10 million yuan [1] - The detailed capital flow for individual stocks in the biodiesel sector is provided in a table [1]

Group 1 - The core point of the news is that Fengbei Biotechnology's stock has experienced a decline of 2.54%, with a total market value of 7.937 billion yuan and a cumulative drop of 6.73% over three consecutive days [1] - Fengbei Biotechnology, established on July 25, 2014, focuses on the comprehensive utilization of waste oil resources, with 91.18% of its revenue coming from this segment, including 79.60% from bio-based materials and 11.58% from biofuels [1] - The company's stock price is currently at 55.31 yuan per share, with a trading volume of 189 million yuan and a turnover rate of 10.80% [1] Group 2 - E Fund's fund holds a small position in Fengbei Biotechnology, with 88 shares representing 0.0002% of the circulating shares, ranking as the fourth largest holding [2] - The fund has incurred a floating loss of approximately 126.72 yuan today and a total floating loss of 351.12 yuan during the three-day decline [2] - E Fund's fund has a total asset size of 5.93 billion yuan, with a year-to-date return of 15.3% and a cumulative return of 20.92% since inception [2]

Core Viewpoint - The biodiesel sector experienced a decline of 1.1% on February 10, with Fengbei Bio leading the drop. The Shanghai Composite Index rose by 0.13%, while the Shenzhen Component Index increased by 0.02% [1]. Group 1: Market Performance - The closing price of Fengbei Bio was 56.75, reflecting a decrease of 3.21% [1]. - The biodiesel sector saw a net outflow of 56.84 million yuan from main funds, while retail investors contributed a net inflow of 46.01 million yuan [1]. - The trading volume for the biodiesel sector was significant, with stocks like Zhongliang Technology and Haixin Energy showing notable trading activity [1]. Group 2: Individual Stock Analysis - Zhongliang Technology closed at 6.43, down by 0.77%, with a trading volume of 217,100 shares [1]. - Fengbei Bio had a net outflow of 8.37 million yuan from main funds, while retail investors contributed a net inflow of 5.62 million yuan [2]. - The stock of Zhuoyue New Energy closed at 76.28, down by 1.56%, with a significant net outflow of 19.20 million yuan from main funds [2].

Core Viewpoint - Fengbei Bio (603334) has experienced significant stock price fluctuations, with a recent increase of 25.93% to 59.3 yuan as of February 6, 2026, indicating strong market interest and trading activity [1][8]. Trading Information Summary - Fengbei Bio was listed on the "Dragon and Tiger List" for two consecutive days due to a daily turnover rate reaching 20% on February 5 and 6, 2026, marking its second appearance in the last five trading days [2][5]. - The stock also saw a cumulative price deviation exceeding 20% over two consecutive trading days, indicating abnormal trading activity [8]. Company Development and Products - Established in 2014, Fengbei Bio focuses on the comprehensive utilization of waste oil resources and has entered a rapid growth phase since 2018, emphasizing bio-based materials and biofuels [3]. - The main business includes waste oil resource utilization, with products such as bio-based materials (e.g., pesticide and fertilizer additives) and biofuels (e.g., biodiesel) [3][4]. - In the first half of 2025, the company produced 47,706.75 tons of biodiesel and 142,814.10 tons of industrial-grade mixed oil [4][5]. Market and Regulatory Environment - The company holds ISCC certification, allowing it to enter the EU market, which has stringent requirements for biofuel products [6]. - The revised Renewable Energy Directive (RED) aims to increase the EU's renewable energy target to at least 42.5% by 2030, impacting the biofuel market [6]. Client Relationships - Fengbei Bio collaborates with major global commodity traders and end customers, including TRFIGUR, GLENCORE, and SHELL, for its biodiesel sales [6]. - The company has established partnerships with key SF manufacturers for the sale of industrial-grade mixed oil [6]. Raw Material Sourcing - Waste oil is sourced from food processing, chemical companies, and kitchen waste treatment enterprises, with a nationwide supply network and efforts to expand overseas [7].

Core Viewpoint - The stock of Suzhou Fengbei Biotechnology Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days on February 4 and 5, 2026, prompting a review of the situation by the company [2][4]. Group 1: Stock Trading Abnormality - The company's stock price showed a significant deviation, with a cumulative increase of over 20% on February 4 and 5, 2026, classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [2][4]. - The company conducted a self-examination and confirmed that there were no undisclosed significant matters apart from those already disclosed [2][6]. Group 2: Operational Status - The company reported that its production and operational activities are normal, with no significant changes in market conditions or industry policies, and no substantial fluctuations in production costs or sales [5]. - There are no major undisclosed matters involving the company, including significant asset restructuring, share issuance, acquisitions, or other major corporate actions [6]. Group 3: Media and Market Rumors - The company found no media reports, market rumors, or trending concepts that could significantly impact its stock price during the abnormal trading period [7]. - Company executives and major shareholders did not engage in buying or selling the company's stock during the period of abnormal trading fluctuations [8].

Core Viewpoint - Suzhou Fengbei Biotechnology Co., Ltd. experienced significant stock price fluctuations, with a cumulative closing price increase exceeding 20% over two consecutive trading days, triggering abnormal trading conditions as per Shanghai Stock Exchange regulations [2][4]. Group 1: Stock Trading Abnormalities - The company's stock price increased by more than 20% cumulatively on February 4 and 5, 2026, indicating abnormal trading activity [2][4]. - The company confirmed that there are no undisclosed significant matters affecting the stock price, following inquiries with its controlling shareholder and actual controller [6][8]. Group 2: Company Operations and Major Events - The company reported that its production and operational activities are normal, with no significant changes in market conditions, industry policies, production costs, or sales [5]. - There are no major undisclosed events or plans, such as asset restructuring or significant business collaborations, that could impact the company [6]. Group 3: Media and Market Rumors - The company found no media reports, market rumors, or trending concepts that could significantly affect its stock price [7]. Group 4: Board and Management Assurance - The board of directors confirmed that there are no undisclosed matters that should have been reported according to the Shanghai Stock Exchange regulations, and previous disclosures do not require correction or supplementation [11].